| Index | — | P/E | 20.34 | EPS (ttm) | 1.46 | Insider Own | — | Shs Outstand | 418.52M | Perf Week | -3.67% |
| Market Cap | 12.43B | Forward P/E | 12.43 | EPS next Y | 2.39 | Insider Trans | — | Shs Float | 418.28M | Perf Month | 11.74% |
| Enterprise Value | 15.40B | PEG | 2.55 | EPS next Q | 1.21 | Short Float | 0.97% | Perf Quarter | -7.62% | ||
| Income | 635.00M | P/S | 1.97 | EPS this Y | 10.37% | Short Ratio | 2.57 | Perf Half Y | -4.69% | ||
| Sales | 6.30B | P/B | 2.40 | EPS next Y | 8.97% | ROA | 5.81% | Short Interest | 4.04M | Perf YTD | -9.48% |
| Book/sh | 12.38 | P/C | 16.49 | EPS next 5Y | 7.98% | ROE | 12.25% | 52W High | 37.09 -19.92% | Perf Year | -16.99% |
| Cash/sh | 1.80 | P/FCF | 14.54 | EPS past 3/5Y | 42.28% 7.14% | ROIC | 8.85% | 52W Low | 26.12 13.71% | Perf 3Y | 35.55% |
| Dividend Est. | 0.62 (2.10%) | EV/EBITDA | 10.30 | Sales past 3/5Y | 5.73% 6.21% | Gross Margin | 68.18% | Volatility | 1.25% 1.58% | Perf 5Y | -16.74% |
| Dividend TTM | 0.79 (2.67%) | EV/Sales | 2.44 | EPS Y/Y TTM | 28.07% | Oper. Margin | 16.69% | ATR (14) | 0.56 | Perf 10Y | -3.29% |
| Dividend Ex-Date | Oct 02, 2026 | Quick Ratio | 1.11 | Sales Y/Y TTM | 5.99% | Profit Margin | 10.08% | RSI (14) | 57.96 | Recom | 2.83 |
| Dividend Gr. 3/5Y | 0.53% 0.32% | Current Ratio | 2.14 | EPS Q/Q | 10.26% | SMA20 | 3.06% | Beta | 0.55 | Target Price | 31.91 |
| Payout | 52.32% | Debt/Eq | 0.72 | Sales Q/Q | 4.59% | SMA50 | 4.89% | Rel Volume | 1.19 | Prev Close | 30.41 |
| Employees | 18,362 | LT Debt/Eq | 0.62 | Earnings | Feb 23 | SMA200 | -4.40% | Avg Volume | 1.45M | Price | 29.70 |
| IPO Date | Nov 16, 1999 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.72% -10.44% | Net Debt/EBITDA | 1.98 | Volume | 1,730,142 | Change | -2.33% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-11-26 | Reiterated | Berenberg Bank | $34 | |
| Aug-06-26 | Downgrade | JP Morgan | Overweight → Neutral | |
| Aug-05-26 | Downgrade | Barclays | Equal Weight → Underweight | |
| May-11-26 | Reiterated | Bernstein | Market Perform | $36 → $32 |
| May-11-26 | Reiterated | Canaccord Genuity | Hold | $32 → $30 |
| Apr-24-26 | Reiterated | Canaccord Genuity | Hold | $35 → $32 |
| Oct-14-25 | Downgrade | Bernstein | Outperform → Market Perform | $38 |
| Aug-18-25 | Reiterated | Canaccord Genuity | Hold | $27 → $36 |
| Mar-12-25 | Downgrade | UBS | Buy → Neutral | |
| Nov-04-24 | Reiterated | Canaccord Genuity | Buy | $27 |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 6,300 | 6,164 | 5,810 | 5,549 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,988 | 1,957 | 1,731 | 1,654 | — | — | — | — | — | |
| Gross Profit | 4,312 | 4,207 | 4,079 | 3,895 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 3,115 | 3,036 | 2,904 | 2,834 | — | — | — | — | — | |
| Research and Development | 353 | 346 | 343 | 339 | — | — | — | — | — | |
| Other Operating Expense | 31 | 31 | 175 | 297 | — | — | — | — | — | |
| Operating Income | 813 | 794 | 657 | 425 | — | — | — | — | — | |
| Interest Expense | 130 | 141 | 150 | 133 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 114 | 126 | -9 | -2 | — | — | — | — | — | |
| Net Income Before Taxes | 797 | 779 | 498 | 290 | — | — | — | — | — | |
| Income Taxes | 162 | 154 | 86 | 27 | — | — | — | — | — | |
| Consolidated Net Income | 635 | 625 | 412 | 263 | — | — | — | — | — | |
| Net Income From Continuing Operations | 635 | 625 | 412 | 263 | — | — | — | — | — | |
| Net Income | 635 | 625 | 412 | 263 | — | — | — | — | — | |
| EPS (Recurring) | 1.50 | 1.46 | 0.94 | 1.20 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.50 | 1.46 | 0.94 | 1.20 | — | — | — | — | — | |
| EPS (Diluted) | 1.46 | 1.44 | 0.94 | 1.20 | — | — | — | — | — | |
| EBITDA | 1,495 | 1,450 | 1,441 | 1,268 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 20.34 | 22.78 | 26.15 | 22.73 | — | — | — | — | — | |
| Price To Sales Ratio | 2.03 | 2.30 | 1.85 | 1.07 | — | — | — | — | — | |
| Gross Margin | 68.44 | 68.25 | 70.21 | 70.19 | — | — | — | — | — | |
| Operating Margin | 12.90 | 12.88 | 11.31 | 7.66 | — | — | — | — | — | |
| Net Margin | 10.08 | 10.14 | 7.09 | 4.74 | — | — | — | — | — | |
| Shares Outstanding | 430 | 433 | 438 | 218 | — | — | — | — | — | |
| Market Capitalization | 12,771 | 14,207 | 10,766 | 5,947 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |